Pradeep S Chauhan
Overview
Explore the profile of Pradeep S Chauhan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
152
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Szymanski J, Chauhan P, Chaudhuri A
Clin Cancer Res
. 2025 Jan;
PMID: 39879112
LINE-1 retrotransposons, comprising 17% of the genome, drive cancer instability through hypomethylation. The DIAMOND assay, targeting LINE-1 hypomethylation with bisulfite sequencing of cell free DNA, achieved AUCs of 88% to...
2.
Hashmi A, Greiner L, Chauhan P, Szymanski J, Park S, Olivier K, et al.
Hematol Oncol Clin North Am
. 2024 Dec;
39(2):257-268.
PMID: 39732580
Circulating tumor DNA (ctDNA) is emerging as a transformative biomarker in the management of non-small cell lung cancer (NSCLC). This review focuses on its role in detecting minimal residual disease...
3.
Chauhan P, Alahi I, Sinha S, Ledet E, Mueller R, Linford J, et al.
Clin Cancer Res
. 2024 Aug;
31(1):151-163.
PMID: 39177583
Purpose: Metastatic castration-resistant prostate cancer (mCRPC) resistant to androgen receptor signaling inhibitors (ARSI) is often lethal. Liquid biopsy biomarkers for this deadly form of disease remain under investigation, and underpinning...
4.
Chauhan P, Alahi I, Sinha S, Shiang A, Mueller R, Webster J, et al.
medRxiv
. 2023 Dec;
PMID: 38077092
Metastatic castration-resistant prostate cancer (mCRPC) resistant to androgen receptor (AR)-targeted agents is often lethal. Unfortunately, biomarkers for this deadly disease remain under investigation, and underpinning mechanisms are ill-understood. Here, we...
5.
Nawaf C, Shiang A, Chauhan P, Chaudhuri A, Agarwal G, Smith Z
Transl Oncol
. 2023 Sep;
37:101763.
PMID: 37657155
Up to 430,000 cases of bladder cancer are diagnosed each year worldwide. A proposed method for non-invasive monitoring has been to utilize a "liquid biopsy." Liquid biopsy has been proposed...
6.
Webster J, Dang H, Chauhan P, Feng W, Shiang A, Harris P, et al.
Bioinformatics
. 2023 Aug;
39(8).
PMID: 37549060
Motivation: Detection of genomic alterations in circulating tumor DNA (ctDNA) is currently used for active clinical monitoring of cancer progression and treatment response. While methods for analysis of small mutations...
7.
Semenkovich N, Szymanski J, Earland N, Chauhan P, Pellini B, Chaudhuri A
J Immunother Cancer
. 2023 Jun;
11(6).
PMID: 37349125
Liquid biopsies using cell-free circulating tumor DNA (ctDNA) are being used frequently in both research and clinical settings. ctDNA can be used to identify actionable mutations to personalize systemic therapy,...
8.
Earland N, Chen K, Semenkovich N, Chauhan P, Zevallos J, Chaudhuri A
Semin Radiat Oncol
. 2023 Jun;
33(3):262-278.
PMID: 37331781
Recent breakthroughs in circulating tumor DNA (ctDNA) technologies present a compelling opportunity to combine this emerging liquid biopsy approach with the field of radiogenomics, the study of how tumor genomics...
9.
Habashi M, Chauhan P, Vutla S, Senapati S, Diachkov M, El-Husseini A, et al.
J Med Chem
. 2023 Feb;
66(4):3058-3072.
PMID: 36763536
Transient soluble oligomers of amyloid-β (Aβ) are considered among the most toxic species in Alzheimer's disease (AD). Soluble Aβ oligomers accumulate early prior to insoluble plaque formation and cognitive impairment....
10.
Chauhan P, Shiang A, Alahi I, Sundby R, Feng W, Gungoren B, et al.
NPJ Precis Oncol
. 2023 Jan;
7(1):6.
PMID: 36658307
Circulating tumor DNA (ctDNA) sensitivity remains subpar for molecular residual disease (MRD) detection in bladder cancer patients. To remedy this problem, we focused on the biofluid most proximal to the...